Hydrophilic bile acids (Bas) are another pharmacological approach for the treatment of NASH, as they can control both glucose and lipid metabolism via activating the farnesoid X receptor (FXR) [92]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.